Evotec SE (ETR:EVT)
Germany · Delayed Price · Currency is EUR 5.40
-0.06 (-1.13%)
At close: Mar 6, 2026
Evotec SE Revenue
In the year 2024, Evotec SE had annual revenue of 796.97M EUR with 1.99% growth. Evotec SE had revenue of 163.89M in the quarter ending September 30, 2025, a decrease of -5.75%.
Revenue
796.97M
Revenue Growth
+467.20%
P/S Ratio
1.27
Revenue / Employee
157.96K
Employees
4,788
Market Cap
957.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 250.52M | 50.01% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | 446.44M | 71.03M | 18.92% |
| Dec 31, 2018 | 375.41M | 334.83M | 825.21% |
| Dec 31, 2006 | 40.58M | -1.26M | -3.02% |
| Dec 31, 2005 | 41.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.58B |
| Siemens Healthineers AG | 23.30B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.10B |
| Redcare Pharmacy NV | 2.94B |
| Gerresheimer AG | 2.25B |
| Carl Zeiss Meditec AG | 2.20B |
| RHÖN-KLINIKUM Aktiengesellschaft | 1.95B |
Evotec SE News
- 2 months ago - Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access - Accesswire
- 2 months ago - Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations - Accesswire
- 3 months ago - Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz - Accesswire
- 3 months ago - Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome - Accesswire
- 4 months ago - Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership - Accesswire
- 4 months ago - Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities - Accesswire
- 4 months ago - In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties - Accesswire
- 4 months ago - Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025 - Accesswire